OTC : BIOYF

BioSyent Inc.

$10.79 USD

$0.07 (0.65%)

Volume
130
Average Volume
2.37K
Market Capitalization
$123.42M
P/E Ratio
18.52
Dividend Yield
1.40%
Price Target
Year High
$12.00
Year Low
$7.63
Day High
—
Day Low
—
Payout Ratio
$0.26
Current Ratio
$1.89
Company Overview

OTC

René C. Goehrum

Medical - Pharmaceuticals

Healthcare

BIOYF

711

CA

USD

https://www.biosyent.com

905-206-0013

090690108

N/A

Liquidity Metrics

0.12

1.89

1.21

0.37

0.26

Sales & Valuation

$43.02M

3.73

3.78

13.52

1.12

Profitability

$0.78

$9M

19.65%

26.44%

22.05%

14.46%

P/E Metrics

18.52

1.06

1.06

Analyst Price Target & Rating

Buy

4/5

0 Analysts

%

Financial Health Scores

8.31

5/9

$14.8M

$62.65M

$17.54M

$11.99M

Key Metrics (TTM)

$170.68M

3.71

13.01

1.89

22.05%

17.03%

5.31%

7.39%

$8.44

158 days

Company Executives
Name Title
Marnie Mccormick Vice President & GM
René C. Goehrum Chairman, Chief Executive Officer & President
Robert J. March Vice President of Finance & Chief Financial Officer
Neelu Atwal Director of Human Resources
Joost van der Mark Vice President of Corporate Development
Poll Results

No votes yet today — be the first to share your view!

About BioSyent Inc. (OTC:BIOYF) Stock

BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Ge ... lclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. BioSyent Inc. was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. The company was incorporated in 2006 and is headquartered in Mississauga, Canada.

BioSyent Inc. (OTCMKTS:BIOYF) Short Interest Down 47.3% in July

2026-07-30 01:41:25

BioSyent Inc. (OTCMKTS:BIOYF - Get Free Report) was the recipient of a significant decline in short interest during the month of July. As of July 15th, there was short interest totaling 4,285 shares, a decline of 47.3% from the June 30th total of 8,126 shares. Based on an average trading volume of 2,510 shares, the

BioSyent to Present at Planet MicroCap Las Vegas

2026-06-15 09:35:00

MISSISSAUGA, Ontario, June 15, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be attending the Planet MicroCap Las Vegas investor conference in Las Vegas, Nevada from June 16th to June 18th, 2026 at the Bellagio Hotel. Mr. René Goehrum, President and CEO of BioSyent, will be presenting in person to attendees at the conference on Wednesday, June 17th at 4:00pm PDT.

BioSyent Announces Health Canada Approval of Thyconvi™ (levothyroxine oral solution)

2026-05-19 09:52:00

MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.

BioSyent Declares Second Quarter 2026 Dividend

2026-05-14 18:01:00

MISSISSAUGA, Ontario, May 14, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.055 per common share, payable in Canadian Dollars on June 15, 2026, to shareholders of record at the close of business on May 29, 2026. This second quarter 2026 dividend compares to a first quarter dividend of $0.055 per common share. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors.

BioSyent Releases Financial Results for First Quarter 2026

2026-05-14 18:00:00

MISSISSAUGA, Ontario, May 14, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the first quarter (Q1) ended March 31, 2026. Key highlights include:

Frequently Asked Questions

What is the current BioSyent Inc. (BIOYF) stock price?

BioSyent Inc.(OTC:BIOYF) stock price is $10.79 in the last trading session. During the trading session, BIOYF stock reached the peak price of $12 while $7.63 was the lowest point it dropped to. The percentage change in BIOYF stock occurred in the recent session was 0.65% while the dollar amount for the price change in BIOYF stock was $0.07.

BIOYF's industry and sector of operation?

The OTC listed BIOYF is part of Medical - Pharmaceuticals industry that operates in the broader Healthcare sector.

Who are the executives of BIOYF?

Marnie Mccormick | Vice President & GM
René C. Goehrum | Chairman, Chief Executive Officer & President
Robert J. March | Vice President of Finance & Chief Financial Officer
Neelu Atwal | Director of Human Resources
Joost van der Mark | Vice President of Corporate Development

How many employees does BIOYF have?

Number of BIOYF employees currently stands at 711. BIOYF operates from 2476 Argentia Road, Mississauga, ON L5N 6M1, CA.

Link for BIOYF official website?

Official Website of BIOYF is: https://www.biosyent.com

How do I contact BIOYF?

BIOYF could be contacted at phone #905-206-0013 and can also be accessed through its website. BIOYF operates from 2476 Argentia Road, Mississauga, ON L5N 6M1, CA.

How many shares of BIOYF are traded daily?

The average number of BIOYF shares traded daily for last 3 months was 2.37K.

What is the market cap of BIOYF currently?

The market value of BIOYF currently stands at $123.42M with its latest stock price at $10.79